Tamsaprost

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Tamsaprost

Property Description
Active ingredient Tamsulosin Hydrochloride
Form Oral Capsule / Tablet
Pharmacological class Selective Alpha-Blocker (alpha1A Adrenergic Receptor Antagonist)
General purpose Relaxation of smooth muscles in the lower urinary tract
Origin Synthetic (Sulfonamide derivative)

Tamsaprost is a synthetic prescription medication that contains the active ingredient Tamsulosin Hydrochloride, a compound formally classified as a selective alpha1A adrenergic receptor antagonist. As an alpha-blocker, it is a single-ingredient pharmaceutical preparation structurally derived from sulfonamides. The compound's use in providing relief for specific urological symptoms characterizes the medication's targeted therapeutic application.

Tamsaprost is designed for oral administration and is typically supplied as an oral capsule or tablet in a modified-release formulation. This specialized design ensures that the Tamsulosin Hydrochloride is released slowly and consistently over an extended period. This allows the medicine to act systemically by maintaining steady levels of the active ingredient, ensuring a sustained pharmacological effect without requiring multiple daily doses.

The primary general purpose of Tamsaprost is to induce the relaxation of smooth muscles in the prostate gland and the bladder neck. By selectively relaxing these specific muscles, the medication reduces the resistance and physical constriction that can impede fluid passage. This targeted action is beneficial in helping to relieve discomfort associated with restricted or difficult urinary flow, resulting in an overall improvement in urine flow.

What side effects are possible with Tamsaprost?

Possible Side Effects and Safety Information

The safety profile of Tamsaprost (Tamsulosin Hydrochloride) is officially documented by regulatory authorities, classifying potential adverse reactions by both frequency and the physiological system affected. The most Common side effects reported in clinical studies generally involve the Nervous System (such as dizziness and headache) and the Reproductive System (including abnormal ejaculation).

Serious adverse reactions, while Rare, are explicitly noted in the regulatory labeling. These include Syncope (fainting), Priapism (a persistent, painful erection), and serious hypersensitivity events such as Angioedema (swelling of the face or throat) and Stevens-Johnson syndrome. A specific risk noted for patients is Intraoperative Floppy Iris Syndrome (IFIS), a complication observed during cataract or glaucoma surgery, irrespective of recent medication use.

Safety notes specify that Orthostatic Symptoms (dizziness upon standing) are observed more frequently at the start of treatment and during dose escalation. Furthermore, the official label imposes constraints, including a contraindication for individuals with severe hepatic impairment. Regulatory documents also mandate that patients must be screened for the presence of prostate cancer prior to and throughout therapy, as symptoms of prostate cancer and BPH can co-exist.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents for Tamsaprost (Tamsulosin Hydrochloride) describe the manifestations and mandated emergency actions in the event of an overdose.


Documented Overdose Manifestations

Overdose may present with signs resulting from severe, acute low blood pressure. The most critical documented manifestation is severe hypotension, which can lead to syncope (fainting). Other reported symptoms may include dizziness, malaise, headache, blurred vision, and upset stomach.


Required Emergency Actions

Immediate medical attention is necessary if an overdose is suspected. Regulatory guidance mandates contacting a poison control center for instruction. Emergency services (such as 911 or the local equivalent) must be called immediately if the affected person has collapsed, experienced a seizure, has trouble breathing, or cannot be awakened.


Management and Monitoring

No specific antidote is known for Tamsaprost overdose. Management focuses on providing cardiovascular support, which typically involves placing the person in a supine position and, if necessary, administering volume expanders or vasopressors. For large quantities, official procedures to impede further absorption, such as gastric lavage or activated charcoal, may be implemented. Monitoring of renal function is recommended, although regulatory information states that dialysis is unlikely to be effective.

Therapeutic Uses of Tamsaprost

Quick Facts: Tamsaprost

  • Primary Use: Management of signs and symptoms related to Benign Prostatic Hyperplasia (BPH).
  • Action: May help improve urine flow in adult males.
  • Benefit: May assist in reducing certain urinary difficulties associated with an enlarged prostate.

Tamsaprost is indicated for the management of the signs and symptoms of benign prostatic hyperplasia (BPH), a condition involving the non-cancerous enlargement of the prostate gland in adult males. The medication may provide therapeutic benefit by addressing the urinary difficulties that can occur with BPH.

Symptoms of BPH that Tamsaprost may help manage include a weak urine stream, urinary hesitancy, and the frequent need to urinate, especially during nighttime hours. By addressing these symptoms, the treatment aims to help improve the flow of urine and may assist in reducing the sensation of incomplete bladder emptying.

It is important to understand that Tamsaprost is intended to manage these signs and symptoms and does not reduce the size of the prostate or affect the underlying disease progression. Its use should be guided by a healthcare professional following an appropriate medical evaluation.

Eligibility and Restrictions for Use

The eligibility for Tamsaprost (Tamsulosin Hydrochloride) is strictly defined by regulatory documents, primarily restricting use to adult males being treated for symptoms of Benign Prostatic Hyperplasia (BPH).

Populations for Whom Use is Contraindicated

Classification Restricted Population
Absolute Prohibition Patients with a known hypersensitivity to tamsulosin or any component.
Absolute Prohibition Patients with a history of orthostatic hypotension (low blood pressure upon standing).
Absolute Prohibition Patients with severe hepatic insufficiency (Severe Liver Disease/Impairment).

Age-Related and Condition-Specific Eligibility

Eligibility Status Specific Population Rule
Not Indicated Pediatric populations (under 18 years old); safety and efficacy have not been established.
Not Indicated Female patients, including those who are pregnant or lactating.
Restricted Use Patients with severe renal impairment (CrCl < 10 mL/min) have not been studied; use is generally not recommended.
Conditional Use Older adults may be used, but greater sensitivity in some older individuals cannot be ruled out.
Conditional Use Patients scheduled for cataract or glaucoma surgery; initiation of treatment is not recommended.

Connection to the Overall Eligibility Profile

Official documents define Tamsaprost as therapy for adult males with BPH, and all contraindications serve to exclude individuals with pre-existing conditions that regulatory data show may be unduly affected. These classifications strictly govern who is eligible for Tamsaprost and under what conditions, ensuring use remains within the safety and efficacy parameters defined by regulatory authorities.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Tamsaprost (Tamsulosin) has documented interactions primarily concerning its metabolism and blood pressure effects, as outlined in regulatory information.

Contraindicated and Cautionary Combinations

Classification Interacting Substance/Class Constraint Basis
Contraindicated Strong CYP3A4 Inhibitors (e.g., ketoconazole) Significant increase in Tamsaprost exposure (AUC/Cmax)
Contraindicated Other Alpha Adrenergic Blocking Agents Risk of severe symptomatic hypotension (additive effect)
Use with Caution Strong/Moderate CYP2D6 Inhibitors (e.g., paroxetine) Increased Tamsaprost exposure
Use with Caution PDE5 Inhibitors (e.g., sildenafil, tadalafil) Potential for additive hypotensive effects

Pharmacokinetic and Food Interactions

The co-administration of Cimetidine increases Tamsaprost's plasma concentration (AUC) and reduces its clearance. While Furosemide causes a minor reduction in plasma concentrations, this change is not considered clinically significant and requires no dosage adjustment.

Regulatory instructions require Tamsaprost to be taken approximately one-half hour following the same meal each day. This is a procedural constraint designed to maintain consistent bioavailability and absorption. Patients identified as CYP2D6 Poor Metabolizers should be managed with caution due to the potential for significantly higher systemic exposure.

Mechanism of Action

How Tamsaprost Works

Tamsaprost (Tamsulosin Hydrochloride) exerts its effects by selectively modulating the Autonomic Nervous System pathways that regulate muscle tension in the lower urinary tract. This action is defined by a precise molecular mechanism that generates predictable physiological consequences.


Selective Blockade of alpha1A Adrenergic Receptors

The primary mechanism involves the drug acting as a highly selective antagonist against the alpha1A subtype of Adrenergic Receptors. These receptors are densely located on the smooth muscle cells of the prostate capsule and the bladder neck. By competitively blocking these sites, Tamsaprost interrupts the signal from the neurotransmitter Norepinephrine that normally triggers muscle contraction, initiating a cascade of relaxation.


Decrease in Dynamic Outflow Resistance

The molecular blockade leads to a reduction in smooth muscle tone at the cellular and tissue level. This physiological change causes the muscle fibers surrounding the proximal urethra to relax, resulting in a decrease of dynamic resistance within the urethra. The mechanism is confined to modulating this dynamic tension. This mechanism enables a targeted adjustment of pathway activity in the lower urinary tract.

Dosage and Administration Information

How Tamsaprost is Used

Tamsaprost (Tamsulosin Hydrochloride) is prescribed for the long-term management of BPH symptoms through a standardized once-daily oral regimen. The administration is governed by rules concerning dosage, timing, and the physical handling of the medicine.


Standard Administration and Dosing

Usage Parameter Instruction
Route of Administration Oral only.
Starting Dose 0.4 mg once daily.
Maximum Dose 0.8 mg once daily.
Timing Relative to Food Taken approximately one-half hour following the same meal each day.
Dose Titration The dose may be increased to 0.8 mg once daily only after two to four weeks if the response to 0.4 mg is assessed as inadequate.

Procedural Constraints and Special Populations

To preserve the extended-release drug profile, Tamsaprost capsules or tablets must be swallowed whole and must not be crushed, chewed, broken, or opened. This procedure is mandatory for the formulation to release the active ingredient correctly.

Regarding specific populations, no dose adjustment is recommended for patients with mild to moderate renal impairment or mild to moderate hepatic impairment. The medicine is not indicated for use in the pediatric population. If treatment is interrupted for a period of several days, therapy must recommence at the starting dose of 0.4 mg once daily.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Tamsaprost


Evidence for Use in Managing Symptoms of Benign Prostatic Hyperplasia (BPH)

Research exploring the use of Tamsaprost primarily focused on adult males whose condition was being studied for symptoms associated with Benign Prostatic Hyperplasia (BPH). The primary source of the evidence is short-term Randomized Controlled Trials (RCTs), where the medication was studied for a defined time interval against an inactive substance. These pivotal studies form the core of the regulatory evidence and have been integrated into multiple systematic reviews and meta-analyses to understand symptom patterns. Research protocols examined the measurements of symptoms taken while Tamsaprost was used.

Studies conducted during periods of increased symptom activity described patterns related to how patients reported their experience. Research has also monitored the use of Tamsaprost in combination with other medications, with some data showing patterns related to symptom measurements compared to results when either medicine was used alone.


Outcomes Evaluated in Clinical Trials

Researchers applied standardized functional scales, such as the International Prostate Symptom Score (IPSS) and the American Urological Association (AUA) Symptom Score, in trials assessing short-term symptom patterns. These scales were used to monitor patient-reported outcomes describing perceived discomfort and frequency of symptoms. Objective measurements were also an established component of the research. Studies monitored functional metrics by tracking the Maximum Urinary Flow Rate ( Q max), which is a measurement of the rate of fluid passage.


What is Still Uncertain About Tamsaprost’s Research Base

Key limitations in the current body of evidence exist, including the fact that the follow-up durations were limited in the gold-standard, placebo-controlled research. The core findings related to symptom measurement are derived from trials that observed responses over defined, short time intervals. While long-term data were collected through extension studies, these open-label research scenarios, which lacked the rigor of blinded comparisons, mean that long-term effects are not fully established under controlled conditions. Comparative evidence is lacking for certain therapeutic pathways, and data for certain pre-existing comorbidities remain insufficient.

Key Studies & References NICE guideline on lower urinary tract symptoms in men (Clinical Guideline Context)

Frequently Asked Questions (FAQ)

Common questions about Tamsaprost (FAQ)


Q: How quickly should I expect to see any effect after starting Tamsaprost?

Clinical studies indicate that some patients may begin to observe an improvement in symptom scores as early as one week after starting Tamsaprost. However, the medicine’s full effect may take longer to develop.


Q: Is Tamsaprost considered a long-term treatment or is it short-term?

Tamsaprost is intended for the long-term management of the symptoms associated with BPH. While initial, core research trials studied the effects over a shorter period, the medicine is intended for ongoing use as part of a treatment plan.


Q: Is Tamsaprost a type of hormonal treatment?

No, Tamsaprost is not a hormonal medicine. Regulatory documents classify it as a Selective Alpha-Blocker, which works by relaxing certain muscles in the urinary tract. It achieves its effect by blocking specific nerve signals, not by changing hormone levels.


Q: Can Tamsaprost cause drowsiness or affect my concentration?

Official safety information states that drowsiness is a known adverse reaction of Tamsaprost. Other central nervous system effects such as dizziness and headache have also been reported in clinical studies.


Q: Do the official patient information leaflets mention anything about driving or operating machinery?

Yes, official guidance suggests that if Tamsaprost causes side effects like dizziness, lightheadedness, or impaired judgment, individuals should avoid engaging in potentially dangerous activities, such as driving a car or operating heavy machinery.


Q: Can Tamsaprost be taken at the same time as common over-the-counter pain relievers?

The official drug label provides specific warnings about potential interactions with certain prescription drug classes, including Nonsteroidal Anti-inflammatory Drugs (NSAIDs), which may include some over-the-counter options. Patients are generally advised to let their healthcare provider know about all medications they use to prevent potential interactions.


Q: Are there any specific types of vitamins or supplements that interact with Tamsaprost?

Official regulatory guidance advises patients to be thorough about all substances they are taking, which includes vitamins, minerals, and herbal supplements. This is due to the potential for interactions between Tamsaprost and other compounds that may not be explicitly listed on the drug label.


Q: Are there restrictions on consuming alcohol while using Tamsaprost?

Official safety notes indicate that alcohol may increase the blood pressure-lowering effects of Tamsaprost. This combination could potentially lead to increased side effects such as dizziness or lightheadedness.


Q: Is there a generic version of Tamsaprost available?

Yes, the active ingredient in Tamsaprost, Tamsulosin Hydrochloride, is widely available under various generic labels in different markets.


Q: What should be done if an allergic reaction is suspected while using Tamsaprost?

If a serious allergic reaction is suspected, such as swelling of the face, tongue, or throat, official guidance describes the need for immediate medical attention in such events. These reactions, though rare, can be severe, so prompt emergency care is required.


Q: Does Tamsaprost have any specific warnings for individuals with heart rhythm issues?

Regulatory safety surveillance documents mention postmarketing reports of several heart rhythm issues, including atrial fibrillation, arrhythmia, and tachycardia (a fast or irregular heartbeat). The incidence of these events has not been fully established in controlled clinical trials.


Q: What is the physical appearance of the Tamsaprost pill or tablet?

The standard Tamsaprost capsule is described in the product information as a gelatin capsule with a light green cap and a yellow body. It also typically features printed identifying markings.


Q: How long does Tamsaprost stay in the body after stopping its use?

The time it takes for the active ingredient to leave the body can vary, but its apparent half-life is cited in official pharmacokinetic data as approximately 9 to 15 hours. The half-life refers to the time needed for the amount of drug in the body to be reduced by half.


Q: Is Tamsaprost approved by health agencies outside of the United States?

Yes, the active ingredient in Tamsaprost is widely recognized and used internationally. It is listed in various international drug databases and is approved by many health agencies around the world.


Q: Why do some people say Tamsaprost is an older drug?

The active ingredient in Tamsaprost, Tamsulosin, was initially approved for medical use in the United States in 1997. Its long history of use since the late 1990s is the basis for it sometimes being described as an older, established medication.


Q: Is it okay to take Tamsaprost before or after exercise?

The only specific regulatory instruction about timing is that the medicine must be taken approximately 30 minutes after the same meal each day. Official product information does not provide specific advice regarding whether it should be taken before or after physical exercise.


Q: Does Tamsaprost contain any common allergens like gluten or lactose?

The product's regulatory documentation describes all inactive ingredients (excipients) in the formulation, which are generally standard pharmaceutical compounds. Specific details on common allergens like gluten or lactose often require checking the particular product’s details and packaging inserts.


How should Tamsaprost be stored and disposed of?

How to Store and Dispose of Tamsaprost?

Official Storage Requirements

Tamsaprost (Tamsulosin Hydrochloride) capsules must be stored at Controlled Room Temperature, which is generally defined as 20 C to 25 C (68 F to 77 F). Brief excursions from this range are acceptable, with temperatures permitted between 15 C and 30 C (59 F to 86 F).

The medication must be kept in a tight container, and all medicines must be stored out of the reach of children, as required by regulatory labeling. It is necessary to maintain the integrity of the medication; therefore, the capsules or tablets must not be crushed, chewed, or opened to preserve the controlled-release properties.

Disposal Instructions

Unused or expired Tamsaprost must be disposed of in accordance with local requirements for pharmaceutical waste. Recommended methods include utilizing a designated drug take-back program. The product is not included on the list of medicines recommended for flushing down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Tamsaprost found in:

A-Z Index: